Workshop for micro, small and mediumsized enterprises (SMEs) "Focus on Scientific and Regulatory Advice"

FRANCE

Afssaps support to innovative structures

26 May 2011 EMA-SME Office



Agence française de sécurité sanitaire des produits de santé

Agenda

• 1) Incentives in place

• 2) Some figures and statistics



Agence française de sécurité sanitaire des produits de santé

Implemented in November 2008

 After 2 years of discussion with internal and external stakeholders in order to establish purposes, limits and procedures.

Scope

Innovative healthcare products

- Without a clear definition, it's an open discussion, but we have some key principles
 - New active substance and / or for new development for unmet medical needs
 - Biological products
 - ex : Advance Therapy Medicinal Product
 - Areas where there is no established scientific, legal and regulatory experience / Guidelines
 - New technology
 - Potential clinical impact...
- Not only medicinal product, also medical device (MD, AIMD, IVD-MD), "combined" products, borderline products...



Aim

• Not to promote innovation, as this is not in Afssaps mission,

But, in the scope of Afssaps public mission, the wish to help development of new healthcare products by taking into account

- the current knowledge of a given condition,
- targeted patient population,
- existing treatment modalities
- specificities of the product being developed.
- regulatory requirements and existing guidelines
- In order to
 - anticipate evaluation difficulties due to the innovation
 - avoid inappropriate development
 - avoid regulatory issues
 - identify new product / technology which needs regulatory modifications
 - accelerate access to patients (CT-ATU-AMM...) due to the quality of the evaluation realized by the applicant.
- With always in mind :
 - Patients' security
 - Patients' needs



Before 2008

Only "scientific advice" (since 1993) Powerful tool, but

> only identified by "pharmaceutical groups", few SME or academic structures asked for it

- Afssaps = Police ?
- No clear contact point ?
- No communication
- usually, only one meeting due to amount of request received
- limited to scientific aspects, no regulatory question
- not always adapted to early stage of development
- not always adapted to academic, SME
- only for medicinal products

Now

Based on

- the qualification of the product (medicine, MD, ?),
- the "regulatory knowledge" of the applicant
- the status of development
- the type of questions

Various tools in place

- Innovation meeting
- Scientific advice
- CTA pre-submission
- Follow-up meeting

With one-stop « shop »

With a pro-active communication (Web


site, News, Bulletins, symposium) on

- New guidelines
- Regulatory changes
- Aid in place (call for projects etc)
- Workshops for SME /Academics.s.aps

"One stop shop" :

- « le référent innovation »
 - A single interface for all innovative structures
 - Advise on regulatory, administrative and procedural issues
 - Facilitate communication
 - Based on demand and If necessary, find / organize the best type of meeting with the applicant (innovation meeting)
 - Organize workshops/training sessions





« Innovation meeting »

For MD, IVD-MD, Medicines, borderline products...

Involve Afssaps transversal network (medicine, medical device, legal, clinical trails, quality, inspection...), but may involve external expertise if needed

Early informal dialogue with Applicants => **ANTICIPATE**

- Regulatory advice on classification
- Regulatory assistance
- Regulatory strategy
- Advice on quality, non-clinical evaluation

• Prepare for future formal steps : scientific advice, CTA pre-submission, FU meeting etc

• Procedure in place with a request form

• <u>http://www.afssaps.fr/Activites/Accompagnement-de-I-innovation/Afssaps-et-innovation/(offset)/0</u>

afssaps 🔾

Key contact : Stéphane PALIES

Scientific Advice Only for medicine.

 \Rightarrow SECURE DEVELOPMENT,

 \Rightarrow Scientific advices are organized in order to provide responses to <u>specific questions</u> such as:

- Clinical development (e.g. endpoints, trial duration, ...)
- Quality aspects (e.g. viral safety, specific tests to be performed during the development of biotechnological product)
- Non clinical

The questions asked by a Company should be as clear as possible and Company's position justified.

A national scientific advice may be useful in identifying the most important points to discuss at the EMEA if an EMEA advice is planned by a company

The advice will not be given:

If a company has already obtained the EMEA advice

When rapporteur and co-rapporteur for MA request have already been designated by the CHMP

http://www.afssaps.fr/Activites/Avis-scientifique-de-medicaments/Avis-scientifique-demedicament/(offset)/0 afssa

Key contact : Caroline AURICHE

- Always free of charge,
- You are free to use or not for the tools; the Afssaps is free to accept or to refuse a request
- Always face to face meetings,
- External expertise is always involved for scientific advice meetings and may or may not be required in the case of innovative meetings
- The delay will depend on the availability of experts; in most cases, meetings are organized within 2 months after the receipt of the request
- Minutes are prepared by the applicants, and reviewed by Afssaps
- FU meetings are proposed only for the most complex products or the most promising ones or for products with potential new risks (nano...), and applicants are usually informed of that possibility at the end of the meeting.
- Procedures in place and available on our website for all the tools,



CTA pre-submission For MD / Medicines Before FIM or First CT in France

 \Rightarrow Give time for evaluation / discussion

This procedure allows the sponsor to ask Afssaps to carry out a preliminary assessment before the official request,

"Real" evaluation

http://www.afssaps.fr/Activites/Medicaments-et-produits-biologiques/Pre-soumission/(offset)/8

If multinational CTs => The Clinical Trials Facilitation Group (CTFG)

 The CTFG offers to clinical trials sponsors a coordinated and simultaneous assessment of multinational clinical trials applications by the national competent authorities concerned, on a voluntary basis : the Voluntary Harmonisation Procedure (VHP) <u>http://www.hma.eu/uploads/media/VHP_version_2_March_2010.pdf</u>



In conclusion :


• No specific financial provisions for SMEs applicable to human healthcare products.


• However, various procedures are in place in order to help development of innovative heathcare products.

- Early meeting with Afssaps => innovation meeting
- Scientific Advice during medicinal product development or before submission of marketing authorization
- Pre-submission procedure for clinical trials
- Not limited to drugs development, but also to MD / IVD-MD
- These procedures are free of charge for all structures, SME or not.


For more information see:


http://www.afssaps.fr/Activites/Accompagnement-de-I-innovation/Afs a for the second se













Number of request



Innovation meeting





Information and Contacts : Afssaps.fr

Agence française de sécurité sanitaire des produits de santé	E land		dfssaps Minimum Andream
Infos de sécurité Activités	Dossiers thématiques Publications Services Partenariats → L'AF557 mapt > Guides en ligns Image: Arrow of the services Image: Arrow of the services Image: Arrow of the services	EXCEPTION Texture Texture Tex	INVITATION Februre EATTOL
Accueil > Activités > Accompagnen	nent > Guides en ligne 📟	Land: Gauges: attachtat an eine Steringeneten de andere de anne de forstendene attachtat anne de forstendene attachtate attachtate attachtate attachtate attachtate attachtate anne de forstendene attachtate at	Adjointe au directeur pénéral de l'Agence transpise de sécurité santáire des produits de santé (Afesaps), est houreuse de vous inviter à une réunion d'échanges :
Activités Soutenir l'innovation > Accompagnement de l'innovation	Accompagnement de l'innovation • Afssaps et innovation • Objectifs, cadre et limites de l'accompagnement de l'innovation • L'accompagnement de l'innovation : Quels produits ? Pour qui ? Comment ? • Contacter et solliciter l'Afssaps dans le cadre de l'accompagnement de l'innovation • Guides en ligne • L'accompagnement de l'innovation : Agir sur son environnement • Evènements Afssaps • Liens utiles	Statistical statist	3erre Rencontre avec les PME innovant dans le domaine de la santé leure de provente 2016, de 14015 a Thets fecuer de partieure de tradit a discorte de leure de partieure de tradit de discorte de leure de la 2016, de 1400 a 1860
> Avis scientifique de médicaments		 verse mais (note) in det and Area active assessment of active assesment of active assess	COMMIN NO CARE OF CARAGES UNK 12.20 NEL107, BOUWARE AVAILUE TRANS 320H Lank Dank Codes (Intellig Partice) - Careful Parya - Nyae 10;
Valoriser l'expertise interne et externe		the second	Cequita 2007, FARsage organise charge années en recorter avec les RME innovant dans le formaine de santé. La previene monotre, es jui 2007, del une cuision de effection une les directations la compagnement de l'innovation à l'Agence et sur les interactions avec les portuns de projets. La desulier recorter, en recorter 2008, a del la consolie de presente inferiore et est envelues options mises en placa aus en la fAgence à l'attention des porteurs de projet interavet et la montain attentes en places aus en la fAgence à l'attention des porteurs de projet interavet, en lien avec la attentes expressiones en 2002.
Poursuivre l'engagement européen et international	Médicaments	terrier franziski politik od 2000 r. 2012, je nacistal kraji politik od 2000 r. 2012, je nacistal kraji politik od 2000 r. 2012 r. 201	La touisième renorme aux pour algentif de fore la point de fore la distance innovation un an après poin tunement et notemment de la pageoire pour l'indiquire et pour Vintage. Cette n'annue estentes à gainement d'express les chargements dels auxenus dans la réglementation. Cette s'économis sont d'agrandes, l'onte an la réalizament de l'anne aux le disposition de la disposition de la Cette d'acconomis sont d'agrandes. J'onte an la réalizament de la disposition de la disposi- citation de la disposition de la disposition de la disposition de la disposition de la disposi- citation de la disposition de la disposition de la disposition de la disposition de la disposi- citation de la disposition de la disposition de la disposition de la disposition de la disposi- citation de la disposition de la disposi- citation de la disposition de la disposition de la disposition de la disposition de la disposi- citation de la disposition de la disposition de la disposition de la disposition de la disposi- tion de la disposition de la dispositione de la disposition de la disposition de la disposition de la disposi- tion de la disposition de la dispos

Dedicated web pages on Afssaps.fr

- Procedure and request form
- But also links
 - To the most important guidelines (EMA, OMS, MEDDEV),
 - Eu and National Regulations,
 - Afssaps specifics documents / Guidelines / FAQ
 - Notice to applicant

Newsleter dedicated innovation

• In order to inform as soon as possible of change in regulation (national and EU), new guidelines, workshops etc

Workshops/training sessions dedicated to SME / academics structures



